Vestmark Advisory Solutions Inc. Makes New $214,000 Investment in Gilead Sciences, Inc. $GILD

Vestmark Advisory Solutions Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,927 shares of the biopharmaceutical company’s stock, valued at approximately $214,000.

Several other hedge funds also recently added to or reduced their stakes in GILD. Brighton Jones LLC increased its holdings in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Edgestream Partners L.P. grew its holdings in Gilead Sciences by 99.0% during the 1st quarter. Edgestream Partners L.P. now owns 18,401 shares of the biopharmaceutical company’s stock worth $2,062,000 after acquiring an additional 9,152 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Gilead Sciences by 24.2% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 94,286 shares of the biopharmaceutical company’s stock valued at $10,565,000 after acquiring an additional 18,368 shares during the last quarter. Finally, Sage Mountain Advisors LLC raised its stake in Gilead Sciences by 10.2% during the 1st quarter. Sage Mountain Advisors LLC now owns 6,735 shares of the biopharmaceutical company’s stock worth $755,000 after acquiring an additional 623 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Morgan Stanley increased their target price on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $143.00 to $153.00 in a research report on Monday. Finally, Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $128.83.

Gilead Sciences Stock Up 2.5%

NASDAQ:GILD opened at $126.44 on Thursday. The stock has a 50-day simple moving average of $116.99 and a 200 day simple moving average of $112.55. Gilead Sciences, Inc. has a one year low of $86.08 and a one year high of $124.86. The company has a market capitalization of $156.88 billion, a price-to-earnings ratio of 25.08, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s payout ratio is currently 48.99%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.